Verastem Oncology Sees Strategic Realignment To Reduce Its Operating Expenses By About 40% For 2020

Verastem Oncology Sees Strategic Realignment To Reduce Its Operating Expenses By About 40% For 2020

Source: 
Reuters
snippet: 

Verastem Oncology announces strategic realignment to reduce its operating expenses, including reduction of the saleforce and non-core clinical research.